ABCL-323 Hypoxia-Specific Imaging Before CAR-T Therapy in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma

Divita Pandita(University of California, San Francisco), Charalambos Andreadis(University of California, San Francisco), Madhav Seshadri(University of California, San Francisco), Rahul Banerjee(University of Washington), Michael Malek‐Ahmadi(Banner Sun Health Research Institute), Weiyun Z. Ai(City College of San Francisco), Chiung‐Yu Huang, Bita Fakhri(University of California, San Francisco), Michelle Leonard(University of Minnesota), Victoria Wang(Dana-Farber Cancer Institute), Lawrence Kaplan(University of California, San Francisco), Michael A. Spinner(Stanford Medicine), Siobhan Larue(University of California, San Francisco), Miguel Hernandez Pampaloni(University of California, San Francisco)
Clinical Lymphoma Myeloma & Leukemia
August 30, 2023
10.1016/s2152-2650(23)01314-9
Cited by 0

Related Papers

Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|683
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
|New England Journal of Medicine|2021|532
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523
<scp>A</scp>rizona <scp>S</scp>tudy of <scp>A</scp>ging and <scp>N</scp>eurodegenerative <scp>D</scp>isorders and <scp>B</scp>rain and <scp>B</scp>ody <scp>D</scp>onation <scp>P</scp>rogram
|Neuropathology|2015|502